Mission Wealth Management LP Sells 158 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Mission Wealth Management LP decreased its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 3.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,373 shares of the medical instruments supplier’s stock after selling 158 shares during the quarter. Mission Wealth Management LP’s holdings in West Pharmaceutical Services were worth $1,731,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. Diversify Advisory Services LLC bought a new stake in shares of West Pharmaceutical Services in the 1st quarter valued at $272,000. Findlay Park Partners LLP grew its position in West Pharmaceutical Services by 30.6% in the 1st quarter. Findlay Park Partners LLP now owns 597,106 shares of the medical instruments supplier’s stock valued at $236,281,000 after purchasing an additional 139,800 shares during the period. Norden Group LLC grew its position in West Pharmaceutical Services by 9.5% in the 1st quarter. Norden Group LLC now owns 2,329 shares of the medical instruments supplier’s stock valued at $922,000 after purchasing an additional 203 shares during the period. Van ECK Associates Corp grew its position in West Pharmaceutical Services by 26.8% in the 1st quarter. Van ECK Associates Corp now owns 13,612 shares of the medical instruments supplier’s stock valued at $5,386,000 after purchasing an additional 2,873 shares during the period. Finally, SpiderRock Advisors LLC acquired a new stake in West Pharmaceutical Services in the 1st quarter valued at $1,753,000. Institutional investors own 93.90% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the transaction, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other West Pharmaceutical Services news, SVP Silji Abraham sold 1,800 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares in the company, valued at $946,030.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the sale, the chief executive officer now directly owns 152,908 shares in the company, valued at approximately $56,063,718.20. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Stock Up 0.5 %

NYSE WST traded up $1.66 during mid-day trading on Friday, hitting $322.56. The company’s stock had a trading volume of 258,764 shares, compared to its average volume of 558,095. The company’s 50 day simple moving average is $337.44 and its 200 day simple moving average is $359.33. West Pharmaceutical Services, Inc. has a twelve month low of $310.00 and a twelve month high of $415.73. The company has a current ratio of 2.61, a quick ratio of 1.95 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $23.50 billion, a price-to-earnings ratio of 42.55, a PEG ratio of 5.67 and a beta of 1.00.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.27. The firm had revenue of $695.40 million for the quarter, compared to the consensus estimate of $670.62 million. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.98 EPS. Analysts anticipate that West Pharmaceutical Services, Inc. will post 7.76 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date is Wednesday, July 31st. West Pharmaceutical Services’s dividend payout ratio is 10.55%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.